Mouse anti human cd107a

Manufactured by BD

Mouse anti-human CD107a is a monoclonal antibody that recognizes the CD107a (LAMP-1) antigen expressed on the surface of cells. CD107a is a lysosomal-associated membrane protein that is transiently expressed on the cell surface during degranulation of cytotoxic T cells and natural killer cells.

Automatically generated - may contain errors

Lab products found in correlation

Penicillin streptomycin, by Thermo Fisher Scientific (6 mentions) Symphony flow cytometer, by BD (3 mentions) Aquavivid viability marker, by Thermo Fisher Scientific (3 mentions) Ic fixation permeabilization kit, by Thermo Fisher Scientific (3 mentions) Hepes, by Thermo Fisher Scientific (3 mentions) Brefeldin a, by BD (3 mentions) Monensin, by BD (3 mentions) Perm wash, by BD (1 mentions) Cd107b, by BD (1 mentions) Golgistop, by BD (1 mentions) Lsr 2 flow cytometer, by BD (1 mentions) Cytofix cytoperm, by BD (1 mentions) Golgiplug, by BD (1 mentions) Cytofix, by BD (1 mentions) Symphony cytometer, by BD (1 mentions)

Spelling variants of this product

Anti-CD107a (32 citations) Anti-human CD107a (5 citations) Mouse anti (2 citations) FITC-labeled mouse anti-human CD107a (clone H4A3, (2 citations)

4 protocols using mouse anti human cd107a

Detecting SARS-CoV-2-specific T cells

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The ICS assay adapted to study SARS-CoV-2-specific T cells was previously described (Tauzin et al., 2021b (link)). PBMCs were thawed and rested for 2 h in RPMI 1640 medium supplemented with 10% FBS, Penicillin-Streptomycin (Thermo Fisher scientific, Waltham, MA) and HEPES (Thermo Fisher scientific, Waltham, MA). 1.7×10⁶ PBMCs were stimulated with a S glycoprotein peptide pool (0.5 μg/mL per peptide from JPT, Berlin, Germany) corresponding to the pool of 315 overlapping peptides (15-mers) spanning the complete amino acid sequence of the S glycoprotein.
Cell stimulation was carried out for 6h in the presence of mouse anti-human CD107a, Brefeldin A and monensin (BD Biosciences, San Jose, CA) at 37 °C and 5% CO₂. DMSO-treated cells served as a negative control, and SEB as positive control. Cells were stained for Aquavivid viability marker (Thermo Fisher scientific, Waltham, MA) for 20 min at 4 °C and surface markers (30 min, 4 °C), followed by intracellular detection of cytokines using the IC Fixation/Permeabilization kit (Thermo Fisher scientific, Waltham, MA) according to the manufacturer’s protocol before acquisition on a Symphony flow cytometer (BD Biosciences) and analysis using FlowJo v10.8.0 software. Abs used are listed in the Table S3.

Nayrac M., Dubé M., Sannier G., Nicolas A., Marchitto L., Tastet O., Tauzin A., Brassard N., Beaudoin-Bussières G., Vézina D., Gong S.Y., Benlarbi M., Gasser R., Laumaea A., Bourassa C., Gendron-Lepage G., Medjahed H., Goyette G., Ortega-Delgado G.G., Laporte M., Niessl J., Gokool L., Morrisseau C., Arlotto P., Richard J., Tremblay C., Martel-Laferrière V., Finzi A, & Kaufmann D.E. (2021). Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. bioRxiv.

+ Open protocol

+ Expand

Evaluating ZIKV-specific PBMC Responses

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cryopreserved PBMCs were thawed, washed and rested overnight at 37° ± 5% CO₂. CEM‐NK^R‐expressing ZIKV NS1 or DC‐SIGN (negative control) was left in media or incubated with anti‐Zika virus NS1 antibody (B4) or plasma samples at different dilutions for 1 h at 4°. PBMCs were counted, added to the culture and incubated at 37° ± 5% CO₂ in the presence of mouse anti‐human CD107a (BD 555800) and CD107b (BD 555804). After 1h, BD GolgiPlug™ (BD 555029) and GolgiStop™ (BD 554724) were added to the wells and incubated at 37° ± 5% CO₂ for another 3 h. Cells were washed and stained with surface Abs anti‐CD3, CD16, CD56 and CD69 for 30 min. Cells were washed, fixed with BD Cytofix™ and acquired on a BD LSR™ II flow cytometer or washed and resuspended in BD Cytofix/Cytoperm™ for 20 min at 4°. The cells were then washed with BD Perm/Wash™ and stained with anti‐IFN‐γ for 30 min at 4°. The cells were washed with BD Perm/Wash™ and fixed with BD Cytofix™. Samples were acquired on a BD LSR™ II flow cytometer, and the data were analysed using the FlowJo software.

Sanchez Vargas L.A., Adam A., Masterson M., Smith M., Lyski Z.L., Dowd K.A., Pierson T.C., Messer W.B., Currier J.R, & Mathew A. (2021). Non‐structural protein 1‐specific antibodies directed against Zika virus in humans mediate antibody‐dependent cellular cytotoxicity. Immunology, 164(2), 386-397.

+ Open protocol

+ Expand

Characterizing S Glycoprotein-Specific T Cell Responses

Check if the same lab product or an alternative is used in the 5 most similar protocols

PBMCs were thawed and rested for 2ch in RPMI 1640 medium supplemented with 10% FBS, Penicillin-Streptomycin (Thermo Fisher scientific, Waltham, MA) and HEPES (Thermo Fisher scientific, Waltham, MA). 2 × 10⁶ PBMCs were stimulated with a S glycoprotein peptide pool (0.5 μg/mL per peptide from JPT, Berlin, Germany) corresponding to the pool of 315 overlapping peptides (15-mers) spanning the complete amino acid sequence of the S glycoprotein.
Cell stimulation was carried out for 6 h in the presence of mouse anti-human CD107A, Brefeldin A and monensin (BD Biosciences, San Jose, CA) at 37°C and 5% CO₂. DMSO-treated cells served as a negative control. Cells were stained for aquavivid viability marker (Thermo Fisher scientific, Waltham, MA) for 20cmin at 4°C and surface markers (30cmin, 4°C), followed by intracellular detection of cytokines using the IC Fixation/Permeabilization kit (Thermo Fisher scientific, Waltham, MA) according to the manufacturer’s protocol before acquisition on a Symphony flow cytometer (BD Biosciences, San Jose, CA). Abs used are listed in the Table S2. Stained PBMCs were acquired on Symphony cytometer (BD Biosciences) and analyzed using FlowJo v10.7.1 software.

Tauzin A., Nayrac M., Benlarbi M., Gong S.Y., Gasser R., Beaudoin-Bussières G., Brassard N., Laumaea A., Vézina D., Prévost J., Anand S.P., Bourassa C., Gendron-Lepage G., Medjahed H., Goyette G., Niessl J., Tastet O., Gokool L., Morrisseau C., Arlotto P., Stamatatos L., McGuire A.T., Larochelle C., Uchil P., Lu M., Mothes W., De Serres G., Moreira S., Roger M., Richard J., Martel-Laferrière V., Duerr R., Tremblay C., Kaufmann D.E, & Finzi A. (2021). A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. Cell Host & Microbe, 29(7), 1137-1150.e6.

+ Open protocol

+ Expand

SARS-CoV-2 T Cell Response Assay

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The ICS assay adapted to study SARS-CoV-2-specific T cells was previously described (Tauzin et al., 2021b (link)). PBMCs were thawed and rested for 2 h in RPMI 1640 medium supplemented with 10% FBS, Penicillin-Streptomycin (Thermo Fisher scientific, Waltham, MA) and HEPES (Thermo Fisher scientific, Waltham, MA). 1.7×10⁶ PBMCs were stimulated with a S glycoprotein peptide pool (0.5 μg/mL per peptide from JPT, Berlin, Germany) corresponding to the pool of 315 overlapping peptides (15-mers) spanning the complete amino acid sequence of the S glycoprotein.
Cell stimulation was carried out for 6 h in the presence of mouse anti-human CD107a, Brefeldin A and monensin (BD Biosciences, San Jose, CA) at 37°C and 5% CO₂. DMSO-treated cells served as a negative control, and SEB as positive control. Cells were stained for Aquavivid viability marker (Thermo Fisher scientific, Waltham, MA) for 20 min at 4°C and surface markers (30 min, 4°C), followed by intracellular detection of cytokines using the IC Fixation/Permeabilization kit (Thermo Fisher scientific, Waltham, MA) according to the manufacturer’s protocol before acquisition on a Symphony flow cytometer (BD Biosciences) and analysis using FlowJo v10.8.0 software. Abs used are listed in the Table S3.

Nayrac M., Dubé M., Sannier G., Nicolas A., Marchitto L., Tastet O., Tauzin A., Brassard N., Lima-Barbosa R., Beaudoin-Bussières G., Vézina D., Gong S.Y., Benlarbi M., Gasser R., Laumaea A., Prévost J., Bourassa C., Gendron-Lepage G., Medjahed H., Goyette G., Ortega-Delgado G.G., Laporte M., Niessl J., Gokool L., Morrisseau C., Arlotto P., Richard J., Bélair J., Prat A., Tremblay C., Martel-Laferrière V., Finzi A, & Kaufmann D.E. (2022). Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. Cell Reports, 39(13), 111013.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!